Tunlametinib: First Approval
Drugs · 2024-08 · 84 (8) · 1005-1010
DOI: 10.1007/s40265-024-02072-x ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drugs, online erschienen am 22.07.2024. Verfasst von Susan J Keam. Beteiligte Einrichtung: Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com. Hauptthemen laut MEDLINE: Drug Approval, Protein Kinase Inhibitors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Tunlametinib (®) is an oral, selective, mitogen-activated protein kinase kinase 1 and 2 (MEK 1/2) inhibitor being developed by Shanghai KeChow Pharma, Inc. for the treatment of solid tumours with RAS and RAF mutations, including melanoma, non-small cell cancer (NSCLC), colorectal cancer (CRC) and neurofibromatosis type 1 (NF1) plexiform neurofibromas. In March 2024, tunlametinib was granted conditional approval in China (based on surrogate endpoints) for use in patients with NRAS-mutated advanced melanoma who have failed anti-PD-1/PD-L1 treatment. This article summarizes the milestones in the development of tunlametinib leading to this first approval for the treatment of solid tumours with RAS and RAF mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.
Zitieren
APA
Keam, S. J. (2024). Tunlametinib: First Approval. Drugs, 84(8), 1005-1010. https://doi.org/10.1007/s40265-024-02072-x
Vancouver
Keam SJ. Tunlametinib: First Approval. Drugs. 2024;84(8):1005-1010. doi:10.1007/s40265-024-02072-x
BibTeX
@article{Keam2024,
author = {Keam, Susan J},
title = {Tunlametinib: First Approval},
journal = {Drugs},
year = {2024},
volume = {84},
number = {8},
pages = {1005--1010},
doi = {10.1007/s40265-024-02072-x}
}
EUVIMED